kallikrein related peptidase 2Genealiases: KLK2A2 · hGK-1 · hK2
Q-omics provides the consensus-scored KLK2 profile across patient tissues and cancer cell-line models. KLK2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLK2 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, KLK2 RNA expression shows 10,325 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where KLK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK2 survival associations across molecular data types. KLK2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK2 RNA expression–survival associations across cancer types. High KLK2 expression shows unfavorable associations in KIRC, THCA and MESO, but favorable associations in ACC, ESCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLK2 RNA expression.
This table summarizes KLK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KLK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK2 shows lower tumor expression in THCA and BRCA and higher tumor expression in KICH, LUSC, HNSC and PRAD. The THCA box plot shows higher KLK2 RNA expression in normal versus tumor tissue (log2 FC = −1.691, t-test p < 0.001).
This table shows molecular features associated with KLK2 in patient tissues and cancer cell lines. In patient samples, KLK2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
